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OBJECTIVEdTo examine the effects of crossing over from optimized multiple daily injection
(MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18
months’ sustained use of SAP.
RESEARCH DESIGN AND METHODSdThe 6-month, single-crossover continuation
phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy
to 420 subjects who completed the 1-year randomized study. The primary outcome was change
in A1C in the crossover group.
RESULTSdA1C values were initially lower in the continuing-SAP group than in the crossover
group (7.4 vs. 8.0%, P, 0.001). A1C values remained reduced in the SAP group. After 3months on
the SAP system,A1Cdecreased to 7.6% in the crossover group (P, 0.001); thiswas a significant and
sustained decrease among both adults and children (P, 0.05).
CONCLUSIONSdSwitching from optimized MDI to SAP therapy allowed for rapid and safe
A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.
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The sensor-augmented pump (SAP)system combines insulin pump andcontinuous glucose monitoring
(CGM) technologies, and its efficacy was
studied in the 1-year randomized phase of
the Sensor-Augmented PumpTherapy for
A1C Reduction (STAR 3) study (1). Com-
pared with subjects onmultiple daily injec-
tions (MDI), those on SAP experienced
greater reductions in A1C levels by 3
months, and this advantage persisted for
the entire study (2). An optional continua-
tion phase allowed MDI subjects to switch
to SAP therapy for 6 months (the crossover
group) and allowed SAP subjects to remain
on uninterrupted SAP therapy (the SAP
group) for a total of 18 months. We exam-
ined the effectiveness of SAP therapy in
subjects transitioning from previously op-
timized MDI therapy and the durability of
glycemic benefits in the SAP group over
18 months.
RESEARCH DESIGN AND
METHODSdSTAR 3 eligibility criteria
included type 1 diabetes, age 7–70 years,
use of MDI with a long-acting insulin an-
alog, A1C between 7.4 and 9.5%, and less
than two severe hypoglycemic events (3)
in the previous year. Subjects were ran-
domized to receive SAP (Paradigm REAL-
Time System, Medtronic MiniMed, Inc.,
Northridge, CA) with insulin aspart or to
MDI using insulins aspart and glargine.
Therapy was optimized individually,
and A1C was obtained at quarterly visits.
Subjects beginning SAP therapy received
training for pumps, CGM sensors, and
therapy management software. All subjects
in the continuation phase were supplied
with sensors and encouraged to wear them
regularly. The primary efficacymeasure was
the change in A1C from 12 to 18months in
both treatment groups; the primary safety
measure was the difference in the rates
of severe hypoglycemia. The study Con-
solidated Standards of Reporting Trials
(CONSORT) diagram and statistical meth-
ods are given in the SupplementaryMaterial.
RESULTSdA total of 420 of 443 sub-
jects completed the study phase and par-
ticipated in the continuation phase; 204 of
216 SAP subjects (94%) and 190 of 204
crossover subjects (93%) completed both
phases of the study. In the SAP group, the
improvement in A1C levels seen during
the study phase was maintained during the
continuation phase (Fig. 1A). Overall mean
(6 SEM) A1C levels for these subjects at 15
and 18 months were not significantly dif-
ferent than the 12-month value of 7.4 6
0.1% (P.0.05). In contrast, patients in the
crossover group realized a significant de-
crease in A1C from 12 months (8.0 6
0.1%) to 15 or 18 months (7.6 6 0.1%,
P , 0.001; Fig. 1A). The significant de-
crease in A1C values in the crossover group
was seen in adult (n = 141; Fig. 1B) and
pediatric (n = 63; Fig. 1C) subjects.
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Subjects in the SAP group were able to
maintain their A1C levels if CGM sensors
were used.40% of the time; subjects who
used sensors less frequently experienced
slight deteriorations in glycemic control.
In the crossover group, maximum im-
provements in A1C were observed with
sensor wear times .60% (Supplementary
Table 1). Mean sensor wear times in the
continuation phase were greater among
adults (616 24% of the time) than among
pediatric subjects (45 6 24% of the time;
P , 0.001). Rates of severe hypoglycemia
were not significantly different among the
SAP and crossover groups in the continua-
tion phase (2.8 vs. 1.0%, respectively; P.
0.05; Supplementary Table 2).
CONCLUSIONSdThe STAR 3 contin-
uation phase results support and extend the
findings of the study phase. In the study
phase, A1C levels were lowered by;0.5 to
0.6% more with SAP treatment than with
MDI. The current data show that a similar
degree of improvement in A1C levels was
achievedwhen subjects switched fromMDI
to SAP after a 12-month period of opti-
mized MDI therapy. Maximal lowering of
A1C levelswas associatedwith CGMsensor
wear times of.60% in the crossover group;
this was similar to wear times associated
with maximal A1C lowering in the SAP
group during the randomized study phase.
The improved A1C levels achieved by
the SAPgroupduring thefirst 12months of
the study were maintained at 15 and 18
months. Sensor wear times of.40% were
required during the continuation phase for
experienced SAP users tomaintain the A1C
benefits achieved during the study phase.
Age-dependent patterns of response
in crossover adult and pediatric subjects
during the continuation phase were sim-
ilar to those observed during the study
phase. Pediatric patients used their sen-
sors less frequently than adults, and lower
wear times were associated with a smaller
reduction in A1C levels. A separate analysis
of STAR 3 data comparing children and ad-
olescents showed additional age-dependent
differences in outcomes and behaviors (4).
Participants were fully aware of the
devices they were using andmay have been
motivated to use the SAP system appropri-
ately. Because the study only enrolled sub-
jects with type 1 diabetes with initial A1C
values of 7.4–9.5% and only included
2 treatment arms, its generalizability may
be limited. The benefits of pump therapy
with or without real-time CGM have been
recently compared (5). Work continues
Figure 1dMean (6 SEM) A1C values of 420 subjects who entered the STAR 3 continuation
phase. All subjects in the continuation phase used SAP therapy. A: All subjects (MDI, n = 204;
SAP, n = 216). B: Adult subjects (MDI, n = 141; SAP, n = 151).C: Pediatric subjects (MDI, n = 63;
SAP, n = 65). *P, 0.001 for between-groups comparison; †P, 0.001 and ‡P, 0.05 for within-
group comparison using the crossover group’s 12-month A1C value as the comparator.
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toward the integration of SAP platforms
and controller algorithms that can safely
reduce hypoglycemic exposure (6) and
may someday provide fully closed-loop
insulin delivery (7).
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